Based on data from the Bolero-2 trial, in July 2012 the US Food and Drug Administration (FDA) approved everolimus in combination with exemestane for use in postmenopausal women with hormone receptor-positive, HER2/neu-negative, advanced breast cancer who have progressed on anastrozole or letrozole. The gene discussed is ERBB2; the disease is breast carcinoma.